|Product Name||(-)-MK-801 maleate|
|Synonyms||(+)-10,11-Dihydro-5-methyl-5H-dibenzo[a,d]cyclohepten-5,10-diyldiammonium maleate;Dizocilpine maleate;(5R,10S)-(+)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate;Dizocilpine maleate;Dizocilpine hydrogen maleate;(+)-MK-801 hydrogen maleate|
|Description||(-)-MK-801 maleate is a potent, selective and non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist with Ki of 30.5 nM that acts at the NMDA receptor-operated ion channel as an open channel blocker. It blocks NMDA receptors in a use- and voltage-dependent manner, since the channel must open for the drug to bind inside it. It anti-convulsant and likely has dissociative anesthetic properties, but it is not used clinically for this purpose due to the discovery of brain lesions, called Olney's lesions in test rats. It were used to treat hyperalgesia in the diabetic neuropathic pain (DNP). It is used in various ischemia treatments. It has been shown to be protective in various models of ischemia as well as to inhibit behavioral sensitization to certain psychostimulants.|
|Quantity||Grams to Kilograms|
|Quality Standard||In-house standard|
The hydrate of Felbamate which is an effective anticonvulsant agent. It was found to be clinically active for probably restraining the effectivity of NMDA.
GV-196771, an indole derivative, has been found to be a non-opioid analgesic agent which is also a NMDA antagonist binds to glycine-binding site and was once st...
LY-221501, a piperidine derivative, has been found to be a NMDA receptor antagonist.
PEAQX(NVP-AAM 077) is a potent and orally active NMDA antagonist with a 15-fold preference for human NMDA receptors with the 1A/2A(IC50=270 nM), rather than 1A/...
Rapastinel, a brain penetrable tetrapeptide, could be a partial agonist of NMDA receptor. It was already finished the Phase II trial for acting as an antidepres...
Ro 25-6981, structurally related to ifenprodil and with no affinity for the known binding sites of non-competitive antagonists such as phencyclidine or MK-801, ...
CP-283097 is NR2B N-Methyl-D-Aspartate receptor antagonist originated by Pfizer. Preclinical trials for the treatment of Migraine and Neurodegenerative disorder...
CGP 31358 is a compound that can bind to a site on the N-methyl-D-aspartate (NMDA) receptor which is coupled to both the transmitter recognition site and the ch...
Besonprodil, a benzimidazolone bioisostere, is an NMDA antagonist that selective for the NR2B subunit.
Apimostinel is a selective partial agonist of an allosteric site of the glycine site of the NMDA receptor complex under investigation by Naurex. Its mechanism o...
Mephenesin is an NMDA receptor antagonist, is a centrally acting muscle relaxant.
Co 101244 hydrochloride
Co 101244 hydrochloride, with strongly neuroprotective effect in vivo and in vitro, is an ifenprodil-like noncompetitive, highly selective antagonist of NR2B-co...
ZL006 is a potent inhibitor of nNOS/PSD-95 interaction. And in mice subjected to mCao and reperfusion, pretreatment with Zl006 attenuated the ischemia-induced i...
(-)-MK-801 maleate is a potent, selective and non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist with Ki of 30.5 nM that acts at the NMDA receptor-...
Memantine is the first in a novel class of Alzheimer's disease medications acting on the glutamatergic system by blocking NMDA receptors.It is also a CYP2B6 and...
Cgp 39551 is a selective and competitive N-methyl-D-aspartate (NMDA) receptor antagonist originated by Novartis. Ki is 310 nM for inhibition of [3H]-CPP binding...
TCN 237 dihydrochloride
TCN 237 dihydrochloride is a potent and NR2B-selective NMDA antagonist (Ki = 0.8 nM), blocks NR2B-mediated calcium influx in Ltk cells (Ki = 9.7 nM).
Ro 25-6981 Maleate
The Maleate salt form of Ro 25-6981 which is a NMDA receptors blocker and has been found to exhibit neuroprotectant activity in vitro and in vivo. IC50: 9 nM.
CGP 43487 has been found to be a NMDA receptor antagonist and was once studied about its influenment of dopaminergic function as a supplement in the treatment o...
L-701,324 is a selective antagonist at the glycine site of the NMDA glutamate receptor. L-701,324 shows a beneficial action in the animal model of parkinsonian ...